| Literature DB >> 32541809 |
Nicole R Karcher1, Deanna M Barch2,3.
Abstract
Following in the footsteps of other large "population neuroscience" studies, the Adolescent Brain Cognitive Development℠ (ABCD) study is the largest in the U.S. assessing brain development. The study is examining approximately 11,875 youth from 21 sites from age 9 to 10 for approximately ten years into young adulthood. The ABCD Study® has completed recruitment for the baseline sample generally using a multi-stage probability sample including a stratified random sample of schools. The dataset has a wealth of measured attributes of youths and their environment, including neuroimaging, cognitive, biospecimen, behavioral, youth self-report and parent self-report metrics, and environmental measures. The initial goal of the ABCD Study was to examine risk and resiliency factors associated with the development of substance use, but the project has expanded far beyond this initial set of questions and will also greatly inform our understanding of the contributions of biospecimens (e.g., pubertal hormones), neural alterations, and environmental factors to the development of both healthy behavior and brain function as well as risk for poor mental and physical outcomes. This review outlines how the ABCD Study was designed to elucidate factors associated with the development of negative mental and physical health outcomes and will provide a selective overview of results emerging from the ABCD Study. Such emerging data includes initial validation of new instruments, important new information about the prevalence and correlates of mental health challenges in middle childhood, and promising data regarding neural correlates of both healthy and disordered behavior. In addition, we will discuss the challenges and opportunities to understanding both healthy development and the emergence of risk from ABCD Study data. Finally, we will overview the future directions of this large undertaking and the ways in which it will shape our understanding of the development of risk for poor mental and physical health outcomes.Entities:
Year: 2020 PMID: 32541809 PMCID: PMC7304245 DOI: 10.1038/s41386-020-0736-6
Source DB: PubMed Journal: Neuropsychopharmacology ISSN: 0893-133X Impact factor: 7.853
Adolescent Brain and Cognitive Development Study.
Examples of previous large population neuroscience studies.
| Study Name | Sample Sizea | Site location | Design | Domains assessed | Ages of sample |
|---|---|---|---|---|---|
| Sanguenay Youth | 1029 | Quebec, Canada | Longitudinal | Imaging, genetic, mental and physical health, and neurocognition | 12–18 |
| NIH-PD | 550 | Six sites across U.S. | Longitudinal | Imaging, mental and physical health, neurocognition, and biospecimen | newborn-adulthood |
| IMAGEN | 2000 | Eight sites across four European countries | Longitudinal | Imaging, genetic, mental and physical health, and neurocognition | 14, 16, 19, 22 |
| PING | 1493 | Ten sites across U.S. | Cross-sectional | Imaging, genetic, neurocognition assessments, and mental and physical health | 3–20 |
| NCANDA | 831 | Five sites across U.S. | Longitudinal | Imaging, mental and physical health, and neurocognition | 12–21 |
| HCP | 1200 | Washington University, University of Minnesota | Cross-sectional | Imaging, genetic, mental and physical health, neurocognition | 22–35 |
| HCP-D | 1350 | Washington University, University of Minnesota, Harvard University, University of California at Los Angeles | Cross- sectionalb | Imaging, genetic, mental and physical health, neurocognition, and biospecimens | 5–21 |
| UK Biobank | Over 500,000 | UK | Longitudinal (1 follow-up assessment) | Imaging, genetic, mental and physical health, neurocognition, and biospecimen | 40–69 |
| Generation R | 9778 | Rotterdam, Netherlands | Longitudinal | Imaging, mental and physical health, neurocognition, and biospecimen | Prenatal-adulthood |
| PNC | ~9498 | Pennsylvania, U.S. | Cross- sectionalb | Imagingc, genetic, mental health, and neurocognition | 8–21 |
| Dunedin Multidisciplinary Health and Development Study | 1037 | Dunedin, New Zealand | Longitudinal | Imaging (at age 45), genetic, mental and physical health, biospecimen, and neurocognition | 3, 5, 7, 9, 11, 13, 15, 18, 21, 26, 32, 38, 45 |
NIH-PD National Institutes of Health Pediatric MRI Database, PING pediatric imaging, neurocognition, and genetics, NCANDA National Consortium on Alcohol and NeuroDevelopment in Adolescence, HCP Human Connectome Project, HCP-D HCP-development, PNC Philadelphia neurodevelopment cohort.
aSample size at baseline for longitudinal studies.
bSubset followed-up longitudinally (HCP-D n = ~240; PNC n = ~500).
cSubset (n = 1445) obtained imaging.